Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Change in Receivables (2024 - 2025)

Indivior Pharmaceuticals has reported Change in Receivables over the past 2 years, most recently at -$6.0 million for Q4 2025.

  • Quarterly results put Change in Receivables at -$6.0 million for Q4 2025, down 250.0% from a year ago — trailing twelve months through Dec 2025 was -$3.0 million (down 400.0% YoY), and the annual figure for FY2025 was -$3.0 million, down 400.0%.
  • Change in Receivables for Q4 2025 was -$6.0 million at Indivior Pharmaceuticals, down from $18.0 million in the prior quarter.
  • Over the last five years, Change in Receivables for INDV hit a ceiling of $18.0 million in Q3 2025 and a floor of -$11.0 million in Q1 2025.